Diabetes and ischemic heart disease

American Heart Journal

Volumn 138, Issue 5 I, 1999, Pages

  McGuire, D K ^a   Granger, C B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLUCOSE; INSULIN; TICLOPIDINE;

CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRESSLER SYNDROME; GLUCOSE BLOOD LEVEL; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN METABOLISM; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

EID: 0032717840     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70037-2     Document Type: Conference Paper

References (85)

1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998;21(suppl I):S5-19.
2. Jiwa F. Diabetes in the 1990s: an overview. Stat Bull 1997;78:2-8.
3. Eschwege E, Simon D, Balkau B. The growing burden of diabetes in the world population. Int Diabetes Fed Bull 1997;42:14-9.
4. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is...or is it? Lancet 1997;350(suppl I):S14-9.
5. Webster MWI, Scott RS. What cardiologists need to know about diabetes. Lancet 1997;350(suppl 1):SI23-7.
6. Savage PJ. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med 1996;124:123-6.
7. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997;126:296-306.
8. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
9. Stout RW. Insulin and atheroma: 20-year perspective. Diabetes Care 1990;13:631-54.
10. Stolar MW. Atherosclerosis in diabetes: the role of hyperinsulinemia. Metabolism 1988;37:1-9.
11. Ducimetiere P, Eschwege E, Papoz L, et al. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980;19:205-10.
12. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
13. Pyorala M, Miettinen H, Laakso M, et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998;98:398-404.
14. Welin L, Erikson H, Larsson B, et al. Hyperinsulinemia is not a major coronary risk factor in elderly men: the study of men born in 1913. Diabetologia 1992;35:766-70.
15. Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo study, 1984-1991. Am J Epidemiol 1994;140:857-69.
16. Ruige JB, Assendelft WJJ, Dekker JM, et al. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998;97:996-1001.
17. Laakso M, Lehto S, Penttila I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88:1421-30.
18. Syvanne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997;350(suppl I):S20-3.
19. Eckel RH. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989;320:1060-8.
20. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 1994;91:9441-5.
21. Stern MP, Mitchell BD, Haffner SM, et al. Does glycemic control of type 2 diabetes suffice to control diabetic dyslipidemia? Diabetes Care 1992;15:638-44.
22. Mazzanti L, Mutus B. Diabetes-induced alterations in platelet metabolism. Clin Biochem 1997;30:509-15.
23. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769-74.
24. Banga JD, Sixma JI. Diabetes mellitus, vascular disease and thrombosis. Clin Hematol 1986;15:465-92.
25. Wilson PWF. Newer metabolic risk factors for heart disease: a brief review. Saudi Med J 1997;18:439-46.
26. Kannel WB, D'Agostino RB, Wilson PWF, et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990;120:672-6.
27. Feener EP. Vascular dysfunction in diabetes mellitus. Lancet 1997;350(suppl I):S9-13.
28. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmia. Lancet 1994;343:155-8.
29. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
30. Mak KH, Moliterno DJ, Granger CB, et al, for the GUSTO-I investigators. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997;30:171-9.
31. Granger CB, Califf RM, Young S, et al, and the TAMI study group. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol 1993;21:920-5.
32. Gray RP, Yudkin JS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J 1993;70:530-6.
33. Woodfield SL, Lundergan CF, Reiner JS, et al, for the GUSTO-I investigators. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996;28:1661-9.
34. Koons JC, Dickerson QH, Bradley EL, et al. Do patients with diabetes mellitus differ from nondiabetic patients with prolonged myocardial ischemia [abstract]? J Am Coll Cardiol 1993;21:239A.
35. Mahaffey KW, Granger CB, Toth CA, et al, for the GUSTO-I investigators. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. J Am Coll Cardiol 1997;30:1606-10.
36. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
37. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
38. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study Report 14. JAMA 1992;268:1292-300.
39. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998;338:1488-97.
40. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
41. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
42. Moliterno DJ, Harrington RA, Newby K, et al. Pronounced reduction in long-term ischemic events with platelet IIb/IIIa antagonism among diabetics with unstable angina: PARAGON 6-month results [abstract]. Circulation 1997;96(suppl I):I-474.
43. Narins CR, Ellis SG, Hammel JP. Does abciximab improve outcome following angioplasty in diabetics? Long-term follow-up results from the EPIC study [abstract]. Circulation 1997;96(suppl I):I-162.
44. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
45. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
46. Kendall MJ, Lynch KP, Hjalmarson A, et al. Beta-blockers and sudden cardiac death. Ann Intern Med 1995;123:358-67.
47. Malmberg K, Herlitz J, Hjalmarson A, et al. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction: retrospective data from two large studies. Eur Heart J 1989;10:423-8.
48. Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285-90.
49. Kjekshus J, Gilpin E, Cali G, et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43-50.
50. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981:2:823-7.
51. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
52. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI): a randomised placebo controlled international trial. Eur Heart J 1985;6:199-226.
53. ISIS-I (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-I. Lancet 1986;2:57-65.
54. Nesto RW, Zarich S. Acute myocardial infarction in diabetes mellitus: lessons learned from ACE inhibition. Circulation 1998;97:12-5.
55. Zuanetti G, Latini R, Maggioni AP, et al, for the GISSI-3 investigators. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997;96:4239-45.
56. Swedberg K, Held P, Kjekshus J, et al, on behalf of the CONSENSUS II study group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
57. Garg A. Treatment of diabetic dyslipidemia. Am J Cardiol 1998;81(4A):47B-51B.
58. Garg A, Grundy SM. Diabetic dyslipidemia and its therapy. Diabetes Rev 1997;5:425-33.
59. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5.
60. Pyorala K, Pedersen T, Kjekshus J, et al, and the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
61. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
62. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
63. Opie LH. Glucose and the metabolism of ischaemic myocardium. Lancet 1995;345:1520-1.
64. Sodi-Pallares D, Testelli MR, Fischleder BL. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol 1962;9:166-81.
65. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-6.
66. Malmberg K, McGuire DK. Diabetes and acute myocardial infarction: the role of insulin therapy. Am Heart J 1999;138:S381-6.
67. Diaz R, Paolasso EA, Piegas LS, et al, on behalf of the ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Metabolic modulation of acute myocardial infarction: the ECLA glucose-insulinpotassium pilot trial. Circulation 1998;98:2227-34.
68. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;75:1124-36.
69. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998;31:950-6.
70. Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol 1994;24:1133-42.
71. + channel blocker. Circulation 1994;90:700-5.
72. Cleveland JC, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Circulation 1997;96:29-32.
73. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970;19:789-830.
74. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J 1999;138:S346-52.
75. Jollis JG, Simpson RJ, Cascio WE, et al. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999;138:S376-80.
76. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, VIII: evaluation of insulin therapy: final report. Diabetes 1982;31(suppl 5):1-78.
77. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med 1996;124:104-9
78. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
79. Stern MP. The effect of glycemic control on the incidence of macrovascular complications of type 2 diabetes. Arch Fam Med 1998;7:155-62.
80. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-68.
81. Moss SE, Klein R, Klein BEK, et al. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994;154:2473-9.
82. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998;158:134-40.
83. Andersson DKG, Svardsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 1995;18:1534-43.
84. Kuusisto J, Mykkanen L, Pyorala K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-7.
85. Abraira C, Colwell J, Nuttall F, et al, and the VACSDM group. Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial. Arch Intern Med 1997;157:181-8.